Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Zhang, Weiguo ^a,b   Mao, Jian Hua ^a   Zhu, Wei ^c   Jain, Anshu K ^d,e   Liu, Ke ^a,b   Brown, James B ^a,b,f   Karpen, Gary H ^a,b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Cellular Biomedicine Group   (China)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Ashland Bellefonte Cancer Center   (United States)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CENTROMERE PROTEIN A; IRINOTECAN; TOPOTECAN;

CANCER; CHEMOTHERAPY; CHROMOSOME; GENE EXPRESSION; GENETIC ANALYSIS; GENOMICS; GENOTOXICITY; HETEROGENEITY; IRRADIATION; SURVIVAL; TUMOR;

ADJUVANT RADIOTHERAPY; ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CENTROMERE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CLINICAL OUTCOME; DISEASE FREE SURVIVAL; EARLY CANCER; GENE CONTROL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC RESISTANCE; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; IC50; LUNG CANCER; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); MUTATION RATE; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; STOMACH CANCER; SURVIVAL PREDICTION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST; BREAST TUMOR; CHROMOSOMAL INSTABILITY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; INFORMATION PROCESSING; KAPLAN MEIER METHOD; LUNG; LUNG TUMOR; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; TISSUE MICROARRAY; TREATMENT OUTCOME;

BREAST; BREAST NEOPLASMS; CENTROMERE; CHEMOTHERAPY, ADJUVANT; CHROMOSOMAL INSTABILITY; DATASETS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84984982003     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12619     Document Type: Article

References (80)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Pihan, G. A., Wallace, J., Zhou, Y. & Doxsey, S. J. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 63, 1398-1404 (2003).
3. Geigl, J. B., Obenauf, A. C., Schwarzbraun, T. & Speicher, M. R. Defining 'chromosomal instability'. Trends Genet. 24, 64-69 (2008).
4. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
5. Siegel, J. J. & Amon, A. New insights into the troubles of aneuploidy. Annu. Rev. Cell Dev. Biol. 28, 189-214 (2012).
6. Kops, G. J. P. L., Weaver, B. A. A. & Cleveland, D. W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5, 773-785 (2005).
7. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
8. Lee, A. J. X. et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 71, 1858-1870 (2011).
9. Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72-76 (2014).
10. Swanton, C. et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512 (2007).
11. Pierotti, M. A., Sozzi, G. & Croce, C. M. Holland-Frei Cancer Medicine 6th edn (BC Decker, 2003).
12. Hiley, C. T. & Swanton, C. Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clin. Med. 14 (Suppl 6) s33-s37 (2014).
13. Roschke, A. V. & Kirsch, I. R. Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability. Cell Cycle 4, 679-682 (2005).
14. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38, 1043-1048 (2006).
15. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220-228 (2010).
16. Artandi, S. E. & DePinho, R. A. Telomeres and telomerase in cancer. Carcinogenesis 31, 9-18 (2010).
17. Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345 (2013).
18. Earnshaw, W. C., Bernat, R. L., Cooke, C. A. & Rothfield, N. F. Role of the centromere/kinetochore in cell cycle control. Cold Spring Harb. Symp. Quant. Biol. 56, 675-685 (1991).
19. Cleveland, D. W., Mao, Y. & Sullivan, K. F. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 112, 407-421 (2003).
20. Janssen, A., van der Burg, M., Szuhai, K., Kops, G. J. & Medema, R. H. Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science 333, 1895-1898 (2011).
21. Zhang, C. Z. et al. Chromothripsis from DNA damage in micronuclei. Nature 522, 179-184 (2015).
22. Allshire, R. C. & Karpen, G. H. Epigenetic regulation of centromeric chromatin: old dogs, new tricks? Nat. Rev. Genet. 9, 923-937 (2008).
23. Black, B. E., Jansen, L. E., Foltz, D. R. & Cleveland, D. W. Centromere identity, function, and epigenetic propagation across cell divisions. Cold Spring Harb. Symp. Quant. Biol. 75, 403-418 (2010).
24. Henikoff, S., Ahmad, K., Platero, J. S. & van Steensel, B. Heterochromatic deposition of centromeric histone H3-like proteins. Proc. Natl Acad. Sci. USA 97, 716-721 (2000).
25. Blower, M. D. & Karpen, G. H. The role of Drosophila CID in kinetochore formation, cell-cycle progression and heterochromatin interactions. Nat. Cell Biol. 3, 730-739 (2001).
26. Earnshaw, W. C. Discovering centromere proteins: from cold white hands to the A, B, C of CENPs. Nat. Rev. Mol. Cell Biol. 16, 443-449 (2015).
27. Nishino, T. et al. CENP-T-W-S-X forms a unique centromeric chromatin structure with a histone-like fold. Cell 148, 487-501 (2012).
28. Blower, M. D., Sullivan, B. A. & Karpen, G. H. Conserved organization of centromeric chromatin in flies and humans. Dev. Cell 2, 319-330 (2002).
29. Foltz, D. R. et al. The human CENP-A centromeric nucleosome-associated complex. Nat. Cell Biol. 8, 458-469 (2006).
30. Hori, T. et al. CCAN makes multiple contacts with centromeric DNA to provide distinct pathways to the outer kinetochore. Cell 135, 1039-1052 (2008).
31. Cheeseman, I. M. & Desai, A. Molecular architecture of the kinetochore-microtubule interface. Nat. Rev. Mol. Cell Biol. 9, 33-46 (2008).
32. Dunleavy, E. M. et al. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 137, 485-497 (2009).
33. Foltz, D. R. et al. Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP. Cell 137, 472-484 (2009).
34. Barnhart, M. C. et al. HJURP is a CENP-A chromatin assembly factor sufficient to form a functional de novo kinetochore. J. Cell Biol. 194, 229-243 (2011).
35. Moree, B., Meyer, C. B., Fuller, C. J. & Straight, A. F. CENP-C recruits M18BP1 to centromeres to promote CENP-A chromatin assembly. J. Cell Biol. 194, 855-871 (2011).
36. Fujita, Y. et al. Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Dev. Cell 12, 17-30 (2007).
37. Cheeseman, I. M., Hori, T., Fukagawa, T. & Desai, A. KNL1 and the CENP-H/I/K complex coordinately direct kinetochore assembly in vertebrates. Mol. Biol. Cell 19, 587-594 (2008).
38. Okada, M. et al. The CENP-H-I complex is required for the efficient incorporation of newly synthesized CENP-A into centromeres. Nat. Cell Biol. 8, 446-457 (2006).
39. Heun, P. et al. Mislocalization of the Drosophila centromere-specific histone CID promotes formation of functional ectopic kinetochores. Dev. Cell 10, 303-315 (2006).
40. Mendiburo, M. J., Padeken, J., Fülöp, S., Schepers, A. & Heun, P. Drosophila CENH3 is sufficient for centromere formation. Science 334, 686-690 (2011).
41. Mishra, P. K. et al. Misregulation of Scm3p/HJURP causes chromosome instability in Saccharomyces cerevisiae and human cells. PLoS Genet. 7, e1002303 (2011).
42. Hu, Z. et al. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res. 12, R18 (2010).
43. Mcgovern, S. L., Qi, Y., Pusztai, L., Symmans, W. F. & Buchholz, T. A. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 14, R72 (2012).
44. Jezequel, P. et al. bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford) 2013, bas060 (2013).
45. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725-731 (2010).
46. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
47. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47-54 (2016).
48. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
49. Okamoto, T. et al. Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact. Cardiovasc. Thorac. Surg. 5, 362-366 (2006).
50. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
51. Zhu, C. Q. et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J. Clin. Oncol. 28, 4417-4424 (2010).
52. Mansell, J. et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res. Treat. 117, 91-98 (2009).
53. Dedeurwaerder, S. et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol. Med. 3, 726-741 (2011).
54. Desmedt, C. et al. Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 29, 1578-1586 (2011).
55. Ashley, E. A. The precision medicine initiative: a new national effort. JAMA 313, 2119-2120 (2015).
56. Winton, T. et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352, 2589-2597 (2005).
57. Esserman, L. J., Thompson, Jr. I. M. & Reid, B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 310, 797-798 (2013).
58. Erhardt, S. et al. Genome-wide analysis reveals a cell cycle-dependent mechanism controlling centromere propagation. J. Cell Biol. 183, 805-818 (2008).
59. Hayashi, T. et al. Mis16 and Mis18 are required for CENP-A loading and histone deacetylation at centromeres. Cell 118, 715-729 (2004).
60. Thiru, P. et al. Kinetochore genes are coordinately up-regulated in human tumors as part of a FoxM1-related cell division program. Mol. Biol. Cell 25, 1983-1994 (2014).
61. Crasta, K. et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 482, 53-58 (2012).
62. Weaver, B. A., Silk, A. D., Montagna, C., Verdier-Pinard, P. & Cleveland, D. W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25-36 (2007).
63. Sheltzer, J. M. & Amon, A. The aneuploidy paradox: costs and benefits of an incorrect karyotype. Trends Genet. 27, 446-453 (2011).
64. Williams, B. R. et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322, 703-709 (2008).
65. Weaver, B. A. & Cleveland, D. W. Does aneuploidy cause cancer? Curr. Opin. Cell Biol. 18, 658-667 (2006).
66. Jamal-Hanjani, M. et al. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Ann. Oncol. 26, 1340-1346 (2015).
67. Kato, T. et al. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 67, 8544-8553 (2007).
68. Zeitlin, S. G. et al. Double-strand DNA breaks recruit the centromeric histone CENP-A. Proc. Natl Acad. Sci. USA 106, 15762-15767 (2009).
69. Lacoste, N. et al. Mislocalization of the centromeric histone variant CenH3/CENP-A in human cells depends on the chaperone DAXX. Mol. Cell 53, 631-644 (2014).
70. Yan, Z. et al. A histone-fold complex and FANCM form a conserved DNA-remodeling complex to maintain genome stability. Mol. Cell 37, 865-878 (2010).
71. Venkitaraman, A. R. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343, 1470-1475 (2014).
72. Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110-120 (2016).
73. Ur-Rehman, S., Gao, Q., Mitsopoulos, C. & Zvelebil, M. ROCsK: a resource for integrative breast cancer data analysis. Breast Cancer Res. Treat. 139, 907-921 (2013).
74. Tang, H. et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 19, 1577-1586 (2013).
75. Cline, M. S. et al. Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2, 2366-2382 (2007).
76. Rousseeuw, P. J. & Croux, C. Alternatives to the median absolute deviation. J. Am. Stat. Assoc. 88, 1273-1283 (1993).
77. Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006).
78. Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005).
79. Jezequel, P. et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res. Treat. 131, 765-775 (2012).
80. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).